These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1634926)

  • 41. Dose escalation study of recombinant human granulocyte-colony-stimulating factor (KRN8601) in patients with advanced malignancy.
    Eguchi K; Sasaki S; Tamura T; Sasaki Y; Shinkai T; Yamada K; Soejima Y; Fukuda M; Fujihara Y; Kunitou H
    Cancer Res; 1989 Sep; 49(18):5221-4. PubMed ID: 2475245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells.
    Winter JN; Lazarus HM; Rademaker A; Villa M; Mangan C; Tallman M; Jahnke L; Gordon L; Newman S; Byrd K; Cooper BW; Horvath N; Crum E; Stadtmauer EA; Conklin E; Bauman A; Martin J; Goolsby C; Gerson SL; Bender J; O'Gorman M
    J Clin Oncol; 1996 Jan; 14(1):277-86. PubMed ID: 8558209
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer.
    Weiss GR; Shaffer DW; DeMoor C; Rinaldi DA; Rodriguez GI; Eckardt JR; Stephens C; Von Hoff DD
    Anticancer Drugs; 1996 Jun; 7(4):402-9. PubMed ID: 8826608
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.
    Thompson JA; Lee DJ; Kidd P; Rubin E; Kaufmann J; Bonnem EM; Fefer A
    J Clin Oncol; 1989 May; 7(5):629-37. PubMed ID: 2651578
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy.
    Furman WL; Fairclough DL; Huhn RD; Pratt CB; Stute N; Petros WP; Evans WE; Bowman LC; Douglass EC; Santana VM
    J Clin Oncol; 1991 Jun; 9(6):1022-8. PubMed ID: 2033415
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Granulocyte-macrophage colony stimulating factor (rh-GM-CSF) in the treatment of chemotherapy-induced neutropenia.
    Gözdasoglu S; Unal E; Yavuz G; Pamir A; Reisli I; Deda G; Tarcan A; Babacan E; Cavdar AO
    J Chemother; 1995 Oct; 7(5):467-9. PubMed ID: 8596135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
    Dinçol D; Samur M; Pamir A; Sencan O; Akbulut H; Yalçin B; Onur H; Demirkazik A; Senler FC; Içli F
    Cancer; 2000 May; 88(9):2033-6. PubMed ID: 10813713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma.
    Vadhan-Raj S; Papadopoulos NE; Burgess MA; Linke KA; Patel SR; Hays C; Arcenas A; Plager C; Kudelka AP; Hittelman WN
    J Clin Oncol; 1994 Apr; 12(4):715-24. PubMed ID: 8151315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor.
    Herrmann F; Schulz G; Lindemann A; Meyenburg W; Oster W; Krumwieh D; Mertelsmann R
    J Clin Oncol; 1989 Feb; 7(2):159-67. PubMed ID: 2644395
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
    Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
    Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation.
    Neidhart J; Mangalik A; Kohler W; Stidley C; Saiki J; Duncan P; Souza L; Downing M
    J Clin Oncol; 1989 Nov; 7(11):1685-92. PubMed ID: 2478670
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration.
    Stute N; Furman WL; Schell M; Evans WE
    J Pharm Sci; 1995 Jul; 84(7):824-8. PubMed ID: 7562431
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I dose intensification study of 2-weekly epirubicin with GM-CSF in advanced cancer.
    Michael M; Toner GC; Olver IN; Fenessy A; Bishop JF
    Am J Clin Oncol; 1997 Jun; 20(3):259-62. PubMed ID: 9167749
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Kornek G; Raderer M; Schenk T; Pidlich J; Schulz F; Globits S; Tetzner C; Scheithauer W
    Cancer; 1995 Oct; 76(8):1356-62. PubMed ID: 8620409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GM-CSF, carboplatin, doxorubicin: a phase I study.
    Poplin EA; Alberts DS; Rinehart JJ; Smith HO; Neidhart JA; Hersh EM
    Cancer Chemother Pharmacol; 1994; 33(4):340-6. PubMed ID: 8281628
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression.
    Blumenthal RD; Sharkey RM; Goldenberg DM
    J Natl Cancer Inst; 1992 Mar; 84(6):399-407. PubMed ID: 1538418
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.
    Estey EH; Kurzrock R; Talpaz M; McCredie KB; O'Brien S; Kantarjian HM; Keating MJ; Deisseroth AB; Gutterman JU
    Br J Haematol; 1991 Mar; 77(3):291-5. PubMed ID: 2012752
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SWOG 8825: melphalan GM-CSF: a phase I study.
    Poplin E; Smith H; Behrens B; Redman B; Flaherty L; Neidhart J; Alberts D
    Gynecol Oncol; 1992 Jan; 44(1):66-70. PubMed ID: 1730428
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase-I trial of Thiotepa, granulocyte-macrophage colony-stimulating factor and prednisone or pentoxifylline in patients with refractory solid tumors.
    Devine S; Ratain M; Janisch L; Richards J; Williams S; Schilsky R; Vogelzang N; Skosey C
    Oncol Rep; 1994 Jan; 1(1):213-6. PubMed ID: 21607339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.